Kimmig A, Gekeler V, Neumann M, Frese G, Handgretinger R, Kardos G, Diddens H, Niethammer D
Department of Hematology and Oncology, Children's University Hospital, Tuebingen, West Germany.
Cancer Res. 1990 Nov 1;50(21):6793-9.
Considering the possibility to overcome drug resistance by other treatment strategies than chemotherapy we investigated the susceptibility of three independently selected multidrug-resistant sublines of the T-lymphoblastoid leukemic cell line CCRF-CEM to lymphokine-activated killer (LAK) cells. We found that two of the multidrug-resistant sublines were significantly less susceptible targets to LAK cells. A third one, however, was as susceptible as the parental CCRF-CEM cell line. Moreover, a multidrug-resistant subline that reverted to an almost drug-sensitive phenotype was observed to be also revertant for resistance against LAK cells. We found an inverse relationship between the expression of the mdr1 gene (P-glycoprotein) and the susceptibility to LAK cells. Verapamil, a calcium channel blocker, while increasing the drug sensitivity of a multidrug-resistant subline, did not induce a reversal of the suppression of LAK susceptibility. The possibility of enhanced resistance to LAK cells of multidrug-resistant cells should be taken into account when one is looking for therapy strategies to overcome multidrug resistance.
考虑到通过化疗以外的其他治疗策略克服耐药性的可能性,我们研究了T淋巴细胞白血病细胞系CCRF-CEM的三个独立选择的多药耐药亚系对淋巴因子激活的杀伤细胞(LAK细胞)的敏感性。我们发现,其中两个多药耐药亚系对LAK细胞的敏感性明显较低。然而,第三个亚系与亲代CCRF-CEM细胞系一样敏感。此外,观察到一个恢复到几乎药物敏感表型的多药耐药亚系对LAK细胞的耐药性也恢复了。我们发现mdr1基因(P-糖蛋白)的表达与对LAK细胞的敏感性之间存在负相关。钙通道阻滞剂维拉帕米虽然增加了一个多药耐药亚系的药物敏感性,但并未诱导LAK敏感性抑制的逆转。在寻找克服多药耐药性的治疗策略时,应考虑多药耐药细胞对LAK细胞耐药性增强的可能性。